Our Approach

New Science Ventures, LLC (NSV) is a New York and London-based venture capital firm which invests in companies using novel scientific approaches in the Life Sciences sector and the Information Technology sector

Learn More

News

January 12, 2021
New Science Ventures announces merger of its portfolio company Achronix with ACE Convergence

New York (NY, US), London (UK), January 12, 2021 – New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, today announces the merger of its portfolio company, Achronix Semiconductor Corporation (“Achronix”), with ACE Convergence Acquisition Corp. NSV

Read More
January 8, 2021
NorthSea Therapeutics reports Positive Phase 2b interim results for icosabutate in NASH patients

Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeks Once-daily oral icosabutate showed dose-dependent, significant, and clinically meaningful improvements in all liver function chemistry, and inflammatory and fibrotic biomarkers with a remarkable

Read More
December 9, 2020
Resolve Therapeutics announces clinically meaningful improvement in patients with Systemic lupus erythematosus in Phase 2a clinical trial

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced results from its Phase 2a study of RSLV-132 in patients with Systemic lupus erythematosus (SLE). Sixty-six patients diagnosed with SLE and a CLASI score of ≥ 10 at screening were enrolled into the study at 19 clinical

Read More
December 3, 2020
Resolve Therapeutics publishes positive Sjogren’s syndrome clinical trial results

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced publication of results from its Phase 2 study of RSLV-132 for the treatment of primary Sjogren’s syndrome (pSS).  The work was published in the leading rheumatology journal, Arthritis and Rheumatology (doi.org/10.1002/art.41489).  The Phase 2 study demonstrated a

Read More
November 20, 2020
NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline

NST becomes a multi-asset clinical development company, beyond NASH Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control A third clinical development program, SEFA 6179, for treating Intestinal Failure- Associated Liver Disease (IFALD) will start Phase 1 studies

Read More
September 28, 2020
ProterixBio Announces Commercial Availability of a Semi-Quantitative COVID-19 Antibody Test

Billerica, MA, September 29, 2020: ProterixBio, Inc. announced today commercial availability of the SARS-CoV-2 (RBD) IgG Antibody test, a semi-quantitative COVID-19 serology assay. It is being offered as a testing service through ProterixBio’s high-complexity clinical testing laboratory. Validation results demonstrated a Positive Percent Agreement (PPA) of 100% for samples acquired

Read More
September 2, 2020
Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions

Interoperability and co-marketing initiatives will bring new options for enterprises, and mobile network operators deploying in-building cellular solutions Menlo Park, California and Paris, France – February 11, 2020 – Dali Wireless, a global leader in wireless fronthaul innovation for virtual RAN, and Amarisoft, a pioneer in software centric 4G LTE

Read More
July 1, 2020
ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital

Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint

Read More
June 25, 2020
Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002 at Digestive Disease Week 2020 Virtual Scientific Program

Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator – Dose-dependent reduction in circulating lymphocytes –– Rapid lymphocyte recovery after cessation of dosing –– Phase 2 study in ulcerative colitis patients in 4Q 2020 – ENCINITAS, California and Cambridge, United Kingdom, June 23, 2020 – Oppilan Pharma, Ltd., a clinical-stage

Read More
March 5, 2020
Perceptimed Founder Jacobs To Speak At Bio2device Group Event

PERCEPTIMED FOUNDER JACOBS TO SPEAK AT BIO2DEVICE GROUP EVENT MOUNTAIN VIEW, CA – April 25, 2014 – “Preventing Drug-Related Patient Injury and Death with Advanced, Cost-Effective Technology” is the topic Alan Jacobs, M.D., Ph.D., CEO and founder of PerceptiMed, will address at the Bio2Device lecture.  The lecture will take place

Read More
March 5, 2020
Perceptimed Awarded NIH Development Grant

PERCEPTIMED AWARDED $1.5M NIH DEVELOPMENT GRANT   MOUNTAIN VIEW, CA – PerceptiMed, Inc., was awarded a $1.5 million grant from the National Institutes of Health (NIH) to develop and test a secure, individual medication system for long-term care facilities.  Dr. Alan Jacobs, CEO and founder of PerceptiMed will serve as

Read More
January 8, 2020
NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic

Two new US investors; lead investor, venBio Partners and Sofinnova Investments, join syndicate of existing investors Richard Gaster, M.D., Ph.D., Principal at venBio Partners, and Maha Katabi, Ph.D., CFA, Partner at Sofinnova Investments join the Board Proceeds will be used to progress the SEFA development pipeline: Completion of Phase 2b

Read More
December 21, 2019
2019: A Look Back

2019 was an exciting and busy year for us! As we take a look back at some of our milestones, we’d like to give a big thank you to all of our publishers. We’re looking forward to what’s in store in the coming year! We’re happy to report that 2019

Read More
November 13, 2019
EXTEN Technologies and AIC to Provide NVMe-oF Storage Solutions Optimized for Supercomputing

AIC Shark Ultra-High-Performance Storage Target Delivers 80GB/S of Random IOPs in 2U with EXTEN NVMe-oF HyperDynamic Software Austin, November 14, 2019 – AIC and EXTEN® Technologies have partnered to provide a dense and scalable, software-defined NVMe-oF solution with record-breaking performance, advanced management, provisioning, and RAID data protection services. This disaggregated

Read More
November 9, 2019
For Digital Publishers, GTxcel’s New Content Hub is a Potential Game Changer

Faced with a growing ecosystem of platforms and distribution channels, digital publishers rely on more sophisticated tools to effectively deliver content and maintain their brand cohesiveness. If you’re like most digital publishers, you probably maintain a network of content distribution channels. Your digital edition, branded website, blog, video channel, and

Read More
October 9, 2019
Not All Content is the Same

Introducing the document-centric table of contents. In documents such as whitepapers, research reports, and user manuals, content is typically organized differently than that of standard consumer publications. As an industry-leading publishing platform, our job is to ensure all readers have an exceptional user experience, regardless of the content they are

Read More
September 25, 2019
NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)

Naarden, The Netherlands, 25 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announces dosing of the first patient with icosabutate in a phase 2b dose ranging study (‘ICONA’).

Read More
Previous Next

Our Companies

We focus on sectors that have strong decades-long tailwinds, where we have direct experience and where we can leverage our strong external networks to create value

Learn More

Our Team

The team brings a wealth of investment experience and board expertise in the information technology and life science sectors across US and Europe

Learn More

Contact Us

New York

299 Park Avenue, 41st Floor, New York, NY 10171
T: 212 688 5100 F: 212 308 9196

London

16 Old Queen Street, London SW1H 9HP
T: 020 3981 9092 F: 020 3981 9100